Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Interventional × S-Adenosylmethionine × Clear all

Phase

Phase NA 2 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Interventions

pembrolizumab 341 Cyclophosphamide 333 Carboplatin 268 Gemcitabine 243 Paclitaxel 240 Nivolumab 227 Cisplatin 208 Radiotherapy 188 Bevacizumab 174 fludarabine 163 Dexamethasone 163 Docetaxel 161 Rituximab 153 Capecitabine 144 Oxaliplatin 130 Lenalidomide 129 Fluorouracil 124 Temozolomide 119 Cytarabine 114 Irinotecan 111 Cetuximab 109 Etoposide 108 fludarabine phosphate 105 venetoclax 104 Injections 96 Doxorubicin 96 130-nm albumin-bound paclitaxel 96 Ipilimumab 93 Azacitidine 93 Pemetrexed 89

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡